Enhancing Patient Care in PPF: Strategies for Addressing Unmet Needs and Optimizing Treatment Approaches : Episode 4

Current Treatment Approaches for PPF: Pharmacological and Nonpharmacological

January 14, 2025

By Anna-Maria Hoffmann-Vold, M.D., Ph.D.

Opinion

Video

Anna-Maria Hoffmann-Vold, M.D., Ph.D., discusses the current treatment landscape for progressive pulmonary fibrosis, highlighting nonpharmacological and pharmacological options to manage the disease.

EP: 1.Understanding PPF and Its Risk Factors

EP: 2.PPF Symptoms and Impact on Quality of Life

EP: 3.Diagnosing PPF and the Importance of Early Detection

Now Viewing

EP: 4.Current Treatment Approaches for PPF: Pharmacological and Nonpharmacological

EP: 5.Key Unmet Needs in PPF Management

EP: 6.Emerging Therapies for PPF

EP: 7.Potential Impact of Emerging PPF Treatments on Patient Outcomes and Health Ccare Resource Utilization

EP: 8.Enhancing Patient Care in Progressive Pulmonary Fibrosis: Strategies for Addressing Unmet Needs and Optimizing Treatment Approaches

Video content above is prompted by the following:

What is the current treatment landscape for progressive pulmonary fibrosis, including nonpharmacological and pharmacological options?

Related Content

Enhancing Patient Care in Progressive Pulmonary Fibrosis: Strategies for Addressing Unmet Needs and Optimizing Treatment Approaches

Peter Wehrwein, Managing Editor

March 5th 2025

Article

Progressive pulmonary fibrosis is not a diagnosis so much as a disease behavior and a clinical phenotype, says Anna-Maria Hoffmann-Vold, M.D., Ph.D., of Oslo University Hospital and the expert featured on this MHE K-Cast.

Value-Based Decision-Making in Metastatic Breast Cancer

Ian E. Krop, MD, PhD;Debra Patt, MD, PhD, MBA

September 16th 2021

Article

In this Managed Healthcare Executive® KCast, Ian Krop, M.D., Ph.D., oncologist and associate professor of medicine at Dana-Farber Cancer Institute in Boston, and Debra Patt, M.D., Ph.D., MBA, executive vice president at Texas Oncology in Austin, provide key insights into the value-based care model for patients with HER2-positive metastatic breast cancer (mBC). This article summarizes the highlights of the discussion.